Skip to main content

ASCPT 2024 Annual Meeting Main banner

Oncology (ONC)

Oncology (ONC)

Type here to filter the list

CT-011 - ETHNIC SENSITIVITY ASSESSMENT OF MOSUNETUZUMAB PHARMACOKINETICS (PK) IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL)

Favorite
CT-012 - PHARMACOKINETICS OF BT8009, A BICYCLE TOXIN CONJUGATE (BTC), IN PATIENTS WITH SOLID TUMOR MALIGNANCIES AND VARIOUS DEGREES OF RENAL FUNCTIONS

Favorite
LB-025 - PHARMACOKINETICALLY-GUIDED DOSING OF ORAL SORAFENIB IN PATIENTS WITH PEDIATRIC HEPATOCELLULAR CARCINOMA

Favorite
PT-023 - EFFECT OF STEROID SPARING IMMUNOSUPPRESSIVE AGENTS USED IN THE TREATMENT OF IMMUNE RELATED ADVERSE EVENTS ON TUMOR OUTCOMES IN MELANOMA AND NON-SMALL CELL LUNG CANCER

Favorite
OAI-003 - UNDERSTANDING THE ASSOCIATIONS BETWEEN HIGH-DOSE METHOTREXATE PHARMACOKINETICS AND THE RISK OF TOXICITIES IN INFANTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA.

Favorite
PII-045 - ACETYLATION-DEPENDENT REGULATION OF NUCLEAR PD-L1 IS CRITICAL TO SISTER CHROMATID COHESION IN TRIPLE NEGATIVE BREAST CANCER

Favorite
PII-046 - AN EVALUATION OF THE DRUG INTERACTION POTENTIAL OF ENCORAFENIB IN COMBINATION WITH BINIMETINIB USING THE INJE COCKTAIL IN PATIENTS WITH BRAF V600-MUTANT UNRESECTABLE OR METASTATIC MELANOMA OR OTHER ADVANCED SOLID TUMORS

Favorite
PII-047 - AN OPEN-LABEL BIOEQUIVALENCE STUDY IN HEALTHY VOLUNTEERS TO COMPARE THE PHARMACOKINETICS OF TWO DIFFERENT TABLET STRENGTHS OF SOTORASIB IN THE FED AND FASTED STATE

Favorite
PII-048 - APPARENT FCRN DYSFUNCTION IN CANCER CACHEXIA DECREASES EXTRAVASCULAR IMMUNOGLOBULIN G ABSORPTION.

Favorite
PII-049 - CLINICAL PHARMACOKINETICS OF ABBV-400, A NOVEL C-MET-TARGETING ANTIBODY DRUG CONJUGATE, IN PATIENTS WITH ADVANCED SOLID TUMORS.

Favorite
PII-050 - CLINICAL PHARMACOLOGY OF IMETELSTAT, A FIRST-IN-CLASS OLIGONUCLEOTIDE TELOMERASE INHIBITOR

Favorite
PII-051 - ELRANATAMAB INTEGRATED EXPOSURE-RESPONSE (ER) EFFICACY AND SAFETY ANALYSES IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) USING A CLINICAL UTILITY INDEX (CUI)

Favorite
PII-052 - ETHNIC SENSITIVITY ASSESSMENT OF MOSUNETUZUMAB PHARMACOKINETICS (PK) IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL)

Favorite
PII-053 - EVALUATION OF IMPACT OF PRIOR CAR T THERAPY ON PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF ODRONEXTAMAB, A CD20×CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL).

Favorite
PII-054 - EVALUATION OF PHARMACOKINETICS (PK), SERUM CYTOKINES, AND SAFETY FOLLOWING INTRAVENOUS (IV) OR SUBCUTANEOUS (SC) STEP-UP DOSING OF UBAMATAMAB, A MUC16XCD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RECURRENT OVARIAN CANCER (OC)

Favorite
PII-056 - IMMUNOGENICITY AND SBMCA CHANGE IN THE COMPARISON OF TALQUETAMAB RECOMMENDED PHASE 2 DOSES

Favorite
PII-057 - INTEGRATED PHARMACOKINETIC (PK)/PHARMACODYNAMIC MODELING OF PK, SAFETY, AND EFFICACY DATA TO SUPPORT DOSE OPTIMIZATION OF BMS-986158, A BROMODOMAIN AND EXTRA-TERMINAL INHIBITOR (BETI), IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF).

Favorite
PII-058 - MODEL-BASED META-ANALYSIS (MBMA) OF OBJECTIVE RESPONSE RATE (ORR), PROGRESSION-FREE SURVIVAL (PFS), AND OVERALL SURVIVAL (OS) TO COMPARE PD-1 AND PD-L1 TREATMENT OUTCOMES IN METASTATIC (M) NON-SMALL-CELL LUNG CANCER (NSCLC)

Favorite
PII-059 - MODELING M-PROTEIN DYNAMICS IN SUBJECTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING VENETOCLAX: UTILITY OF EARLY M-PROTEIN MONITORING TO PREDICT PROGRESSION FREE SURVIVAL

Favorite
PII-060 - PHARMACOKINETICS (PK) AND SOLUBLE MET (SMET) PHARMACODYNAMICS (PD) OF REGN5093, A MET X MET BISPECIFIC ANTIBODY, IN PATIENTS (PTS) WITH MET-ALTERED ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC)

Favorite
PII-061 - PHARMACOKINETICS (PK) OF MIRZOTAMAB CLEZUTOCLAX (MIRZO-C) IN PATIENTS WITH RELAPSED AND REFRACTORY SOLID TUMORS: FIRST IN HUMAN STUDY RESULTS

Favorite
PII-062 - PHARMACOKINETICS OF BT8009, A BICYCLE TOXIN CONJUGATE (BTC), IN PATIENTS WITH SOLID TUMOR MALIGNANCIES AND VARIOUS DEGREES OF RENAL FUNCTIONS

Favorite
PII-063 - PHARMACOKINETICS OF TARLATAMAB, A DELTA LIKE LIGAND-3 (DLL3) TARGETED HALF-LIFE EXTENDED BISPECIFIC T-CELL ENGAGER (BITE) IMMUNOTHERAPY IN ADULT PATIENTS WITH PREVIOUSLY TREATED SMALL CELL LUNG CANCER (SCLC)

Favorite
PII-064 - POPULATION PHARMACOKINETIC MODEL FOR THE TGFβR1 INHIBITOR PF-06952229 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS

Favorite
PII-065 - POPULATION PHARMACOKINETICS (POPPK) OF ABBV-383, A B-CELL MATURATION ANTIGEN (BCMA) × CD3 BISPECIFIC T-CELL-REDIRECTING ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM).

Favorite
PII-066 - POPULATION PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSES OF ZOLBETUXIMAB IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Favorite
PII-067 - POPULATION PHARMACOKINETICS OF ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA.

Favorite
PII-068 - REDUCED SYSTEMIC EXPOSURE TO A CAPECITABINE METABOLITE 5'-DFUR IN ABCC4 POLYMORPHISM MAY BE ASSOCIATED WITH INCREASES IN CAMP LEVEL AND SUBSEQUENT UPREGULATION OF THYMIDINE PHOSPHORYLASE

Favorite
PII-069 - THE ANTI-OSTEOCLASTIC EFFECTS AND BONE-AFFINITY PROPERTIES OF GERANYLGERANYL DIPHOSPHATE SYNTHASE INHIBITOR RAM2061

Favorite
PII-070 - TUCATINIB DOES NOT INCREASE PACLITAXEL PLASMA CONCENTRATIONS IN PATIENTS WITH HER2+ GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Favorite
PII-071 - UNDERSTANDING THE ASSOCIATIONS BETWEEN HIGH-DOSE METHOTREXATE PHARMACOKINETICS AND THE RISK OF TOXICITIES IN INFANTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA.

Favorite
PWII-001 - MODEL-BASED META-ANALYSIS (MBMA) OF OBJECTIVE RESPONSE RATE (ORR), PROGRESSION-FREE SURVIVAL (PFS), AND OVERALL SURVIVAL (OS) TO COMPARE PD-1 AND PD-L1 TREATMENT OUTCOMES IN METASTATIC (M) NON-SMALL-CELL LUNG CANCER (NSCLC)

Favorite